ClinicalTrials.gg
TerminatedNCT02141295McCAVEUpdated Mar 25, 2020Results posted

A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer

A Phase 2 interventional study of 5-FU and Bevacizumab in Colorectal Cancer, sponsored by Hoffmann-La Roche. Terminated at 39 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-25.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
197
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies testing oxaliplatin in Colorectal Neoplasms — 21 open to participants now, 25 under way, 6 of them phase 3. Oxaliplatin · Colorectal Neoplasms.

Enrollment
40th of 183
197 · median 50
Started
2014
with 6 others
Phase 2
110 of 206
12 open now
Registered
160th of 206
by date
Lead sponsor
11 of 206
Hoffmann-La Roche

Among the 206 studies testing oxaliplatin in Colorectal Neoplasms, this one is the 40th largest by enrollment of the 183 interventional ones that give a count, is one of 7 that started in 2014, is one of 110 in phase 2, and was the 160th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

21 of the 206 studies testing oxaliplatin in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About oxaliplatin

Oxaliplatin: first FDA approval 2002 (ELOXATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies testing oxaliplatin in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This is a Phase 2 multicenter, randomized, parallel arms, double-blind study of vanucizumab to evaluate the efficacy and safety of vanucizumab in combination with oxaliplatin, folinic acid, and 5-fluorouracil (5-FU) (mFOLFOX-6) versus bevacizumab (Avastin) + mFOLFOX-6 in participants with previously untreated metastatic colorectal cancer (mCRC). The study consists of 2 parts: a safety run-in open-label, single-arm part (Part 1) and a randomized, parallel-arms, double-blind part (Part 2). During Part 1 at least 6 eligible participants will receive 2000 milligrams (mg) vanucizumab every 2 weeks + mFOLFOX-6 in order to confirm the dose and schedule that will be used in Part 2. In Part 2, all eligible participants will be randomized in a ratio of 1:1 to receive either mFOLFOX-6 + vanucizumab or mFOLFOX-6 + bevacizumab. Study treatment (induction and maintenance) will be given on Day 1 of each 14-day cycle. Induction therapy will consist of up to 8 cycles of mFOLFOX-6 plus either bevacizumab or vanucizumab. Maintenance therapy will consist of 5-fluorouracil and folinic acid plus either vanucizumab or bevacizumab for up to 24 months or until disease progression, unacceptable toxicity, Investigator decision or consent withdrawal, whichever occurs first.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed mCRC not amenable to potentially curative resection with at least one measurable lesion, as defined by v1.1
  • (World Health Organization) performance status of 0 or 1
  • Adequate hematologic, liver, coagulation, renal, and cardiovascular function
  • Recovery from all reversible AEs of previous medical therapies to baseline or National Cancer Institute (NCI CTCAE) Grade 1, except for alopecia (any grade)
  • Negative serum pregnancy test within 7 days prior to starting study treatment in premenopausal women and women less than (\< 2) years after the onset of menopause

Exclusion criteria

Exclusion Criteria:

  • Any prior systemic therapy (including chemotherapy, antibody therapy, tyrosine kinase inhibitors, immunotherapy, hormonal therapy) before Day 1 of Cycle 1 for treatment of mCRC
  • other than CRC within 5 years prior to randomization, except for those with a minimal risk of or death, such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, ductal carcinoma in situ treated surgically with curative intent
  • Radiotherapy within 28 days and abdominal/ pelvic radiotherapy within 60 days prior to Day 1 of Cycle 1, except palliative radiotherapy to bone lesions within 7 days prior to Day 1 of Cycle 1
  • Treatment with any other agent or participation in another clinical trial with therapeutic intent within 28 days prior to Day 1 of Cycle
  • Pregnant or lactating women
  • Symptomatic central nervous system (CNS) metastases or carcinomatous meningitis. Asymptomatic patients must be clinically stable with regard to their CNS/ meningeal metastatic involvement, have completed previous therapy (including radiation and/ or surgery) at least 4 weeks prior to study drug administration, are not receiving therapy or taper, and are not receiving anti-convulsive medication for any CNS involvement
  • Active infection requiring IV antibiotics
  • Active disease that is not controlled by nonsteroidal anti-inflammatory drugs (NSAIDs), inhaled corticosteroids, or the equivalent of less than or equal to (\</=) 10 mg/day prednisone
  • Sensory peripheral neuropathy greater than or equal to (>/=) Grade 2
  • Significant cardiovascular or cerebrovascular disease within 6 months prior to Day 1 of Cycle 1
  • Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation
  • Current use of anticoagulants at therapeutic doses within 7 days prior to study drug administration. Prophylactic use of unfractioned heparin or low molecular weight heparin is permitted
  • Major surgical procedure, open , or significant traumatic injury within 28 days prior to Day 1 of Cycle 1 or abdominal surgery, abdominal interventions or significant abdominal traumatic injury within 60 days prior to Day 1 of Cycle 1
  • History of intra-abdominal inflammatory process within 6 months prior to Day 1 of Cycle 1 including but not limited to peptic ulcer disease, diverticulitis, or colitis
  • Colonic prosthesis (stent) implant in place
  • History of abdominal or tracheo-oesophageal fistula or gastrointestinal (GI) perforation or intra abdominal abscess within 6 months prior to Day 1 of Cycle 1
  • History of intestinal obstruction and/or clinical signs or symptoms of GI obstruction including sub-occlusive disease related to the underlying disease or a requirement for routine parenteral hydration, parenteral nutrition, or tube feeding within 6 months prior to Day 1 of Cycle 1
  • Chronic daily treatment with NSAID (occasional use for the symptomatic relief of medical conditions, for example headache or fever is allowed)
  • Chronic daily treatment with corticosteroids (dose > 10 mg/day methylprednisolone equivalent) excluding inhaled steroids
  • Evidence of abdominal free air not explained by paracentesis or recent surgical procedure
  • Metastatic disease that involve major airways or blood vessels, or centrally located mediastinal tumor masses (\< 30 millimeter from the carina) of large volume
  • History of bronchopulmonary hemorrhage >/= Grade 2 within 2 months prior to randomization
  • Severe, nonhealing or open wound, active ulcer, or untreated bone fracture
  • Known dihydropyrimidine dehydrogenase deficiency or thymidylate synthase gene polymorphism predisposing the patient for 5-FU toxicity
  • Any other condition, diseases, metabolic dysfunction, active or uncontrolled infections/inflammation, physical examination finding, mental status or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates participation in the clinical study due to safety concerns, compliance with clinical study procedures or that may affect the interpretation of the results
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
197 participants (actual)

Study arms

  • Experimental
    Part 1 (Induction): Vanucizumab + mFOLFOX-6

    Participants will receive vanucizumab at a dose of 2000 milligram (mg) as intravenous (IV) infusion; oxaliplatin at a dose of 85 mg per meter-squared (mg/m\^2) as IV infusion; folinic acid at a dose of 400 mg/m\^2 as IV infusion; and 5-FU at a dose of 400 mg/m\^2 as starting IV bolus followed by 2400 mg/m\^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).

    Drug: 5-FU · Drug: Folinic acid · Drug: Oxaliplatin · Drug: Vanucizumab

  • Experimental
    Part 1 (Maintenance): Vanucizumab + 5-FU + Folinic acid

    Participants will receive vanucizumab at a dose confirmed during induction as IV infusion; folinic acid at a dose of 400 mg/m\^2 as IV infusion; and 5-FU at a dose of 400 mg/m\^2 as starting IV bolus followed by 2400 mg/m\^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.

    Drug: 5-FU · Drug: Folinic acid · Drug: Vanucizumab

  • Active comparator
    Part 2 (Induction): Bevacizumab + mFOLFOX-6

    Participants will receive bevacizumab at a dose of 5 milligram per kilogram (mg/kg) as IV infusion; oxaliplatin at a dose of 85 mg/m\^2 as IV infusion; folinic acid at a dose of 400 mg/m\^2 as IV infusion; and 5-FU at a dose of 400 mg/m\^2 as starting IV bolus followed by 2400 mg/m\^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).

    Drug: 5-FU · Drug: Bevacizumab · Drug: Folinic acid · Drug: Oxaliplatin

  • Experimental
    Part 2 (Induction): Vanucizumab + mFOLFOX-6

    Participants will receive vanucizumab at a dose confirmed during part 1 as IV infusion; oxaliplatin at a dose of 85 mg/m\^2 as IV infusion; folinic acid at a dose of 400 mg/m\^2 as IV infusion; and 5-FU at a dose of 400 mg/m\^2 as starting IV bolus followed by 2400 mg/m\^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).

    Drug: 5-FU · Drug: Folinic acid · Drug: Oxaliplatin · Drug: Vanucizumab

  • Active comparator
    Part 2 (Maintenance): Bevacizumab + 5-FU + Folinic acid

    Participants will receive bevacizumab at a dose of 5 mg/kg as IV infusion; folinic acid at a dose of 400 mg/m\^2 as IV infusion; and 5-FU at a dose of 400 mg/m\^2 as starting IV bolus followed by 2400 mg/m\^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.

    Drug: 5-FU · Drug: Bevacizumab · Drug: Folinic acid

  • Experimental
    Part 2 (Maintenance): Vanucizumab + 5-FU + Folinic acid

    Participants will receive vanucizumab at a dose confirmed during part 1 as IV infusion; folinic acid at a dose of 400 mg/m\^2 as IV infusion; and 5-FU at a dose of 400 mg/m\^2 as starting IV bolus followed by 2400 mg/m\^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.

    Drug: 5-FU · Drug: Folinic acid · Drug: Vanucizumab

Interventions

  • Drug5-FU

    5-FU will be administered according to dose and schedule described in respective arm.

  • Bevacizumab will be administered according to dose and schedule described in respective arm.

    Also known as: Avastin

  • Folinic acid will be administered according to dose and schedule described in respective arm.

  • Oxaliplatin will be administered according to dose and schedule described in respective arm.

  • Vanucizumab will be administered according to dose and schedule described in respective arm.

    Also known as: RO5520985

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS), Time to Event

    Efficacy of vanucizumab was evaluated in terms of PFS as Investigator-Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). PFS was defined as the time between randomization and the date of first documented disease progression or death from any cause on study, whichever occurred first. Death on study was defined as death from any cause within 30 days of the last study treatment.

    Time frame: Baseline, every 8 weeks, up to approximately 29 months

Secondary outcomes

  1. Percentage of Participants With Objective Response (ORR) as Assessed Using RECIST v. 1.1

    Efficacy of vanucizumab was evaluated in terms of Percentage of Participants With ORR as Investigator-Assessed Using RECIST v. 1.1. Best Overall Confirmed Response.

    Time frame: Baseline (within 28 days prior to Day 1), then every 8 weeks until progressive disease (PD), start of other anticancer therapy, withdrawal of consent, or death (up to approximately 29 months)

  2. Duration of Objective Response, as Assessed Using RECIST v. 1.1

    Efficacy of vanucizumab was evaluated in terms of duration of objective response as assessed using RECIST v. 1.1. This was computed using the PFS definition with death on study (deaths that occurred outside the 30 days window from the last study treatment are excluded).

    Time frame: Baseline (within 28 days prior to Day 1), then every 8 weeks until PD, start of other anticancer therapy, withdrawal of consent, or death (up to approximately 29 months)

  3. Overall Survival (OS)

    Efficacy of vanucizumab was evaluated in terms of OS as the time from randomization until death from any cause. 99999 = data not estimable due to the low number of deaths.

    Time frame: Baseline until death from any cause (maximum up to approximately 3.5 years)

  4. Percentage of Participants With Adverse Events (AEs)

    Safety is evaluated in terms of percentage of participants with at least one serious adverse event and percentage of participants with at least one adverse event.

    Time frame: Up to approximately 29 months

  5. Number of Participants With Human Anti-human Antibodies (HAHAs) Against Vanucizumab

    Safety is evaluated in terms of number of participants with Human Anti-human Antibodies (HAHAs) Against Vanucizumab.

    Time frame: End of study (EoS, within 28 to 42 days after last dose, latest at 29 months)

  6. Area Under the Plasma Concentration-Time Curve (AUC) of Vanucizumab

    PK profile of vanucizumab was evaluated in terms of AUC

    Time frame: Cycles 1 and 8 of parts 1 and 2

  7. Maximum Observed Plasma Concentration (Cmax) of Vanucizumab

    PK profile of vanucizumab was evaluated in terms of Cmax

    Time frame: Cycles 1 and 8 of parts 1 and 2

  8. Minimum Observed Plasma Concentration (Clast) of Vanucizumab

    PK profile of vanucizumab was evaluated in terms of Clast

    Time frame: Cycles 1 and 8 of parts 1 and 2

  9. Time to Reach Cmax (Tmax) of Vanucizumab

    PK profile of vanucizumab was evaluated in terms of Tmax

    Time frame: Cycles 1 and 8 of parts 1 and 2

  10. Plasma Terminal Half-Life (t1/2) of Vanucizumab

    PK profile of vanucizumab was evaluated in terms of t1/2, values are reported for cycle 8 of both part 1 (safety run-in) and part 2 of the study.

    Time frame: Cycle 8

  11. Plasma Clearance at Steady State (CLss) of Vanucizumab

    PK profile of vanucizumab was evaluated in terms of CLss, values are reported for cycle 8 of both part 1 (safety run-in) and part 2 of the study.

    Time frame: Cycle 8

  12. Volume of Distribution at Steady State (Vss) of Vanucizumab

    PK profile of vanucizumab was evaluated in terms of Vss, values are reported for cycle 8 of both part 1 (safety run-in) and part 2 of the study.

    Time frame: Cycle 8

  13. Cmax Accumulation Ratio (AR) of Vanucizumab

    PK profile of vanucizumab was evaluated in terms of Cmax Ratio, values are reported for cycle 8 of both part 1 (safety run-in) and part 2 of the study.

    Time frame: Cycle 8

07

Results

Posted Mar 25, 2020

Participant flow

Participant flow — Overall Study
MilestoneSafety Run-InVanucizumab + mFOLFOX-6Bevacizumab + mFOLFOX-6
Started89495
Completed200
Not completed69495
Withdrew: Adverse event11811
Withdrew: Physician decision21914
Withdrew: Study terminated by sponsor066
Withdrew: Non-compliance010
Withdrew: Progressive disease33250
Withdrew: Reason not specified0910
Withdrew: Withdrawal by subject094

Outcome measures

PrimaryProgression-free Survival (PFS), Time to Event

Efficacy of vanucizumab was evaluated in terms of PFS as Investigator-Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). PFS was defined as the time between randomization and the date of first documented disease progression or death from any cause on study, whichever occurred first. Death on study was defined as death from any cause within 30 days of the last study treatment.

Time frame:
Baseline, every 8 weeks, up to approximately 29 months
Reported as:
Median · days
Progression-free Survival (PFS), Time to Event
daysVanucizumab + mFOLFOX-6Bevacizumab + mFOLFOX-6
Progression-free Survival (PFS), Time to Event338.0 (312.0 to 381.0)309.0 (284.0 to 352.0)
Statistical analysis
  • Vanucizumab + mFOLFOX-6 vs Bevacizumab + mFOLFOX-6 · Regression, Cox · p = = 0.6753 (log-rank) · Hazard ratio (hr): 0.91 · 95% CI 0.60 to 1.39
SecondaryPercentage of Participants With Objective Response (ORR) as Assessed Using RECIST v. 1.1

Efficacy of vanucizumab was evaluated in terms of Percentage of Participants With ORR as Investigator-Assessed Using RECIST v. 1.1. Best Overall Confirmed Response.

Time frame:
Baseline (within 28 days prior to Day 1), then every 8 weeks until progressive disease (PD), start of other anticancer therapy, withdrawal of consent, or death (up to approximately 29 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Objective Response (ORR) as Assessed Using RECIST v. 1.1
Percentage of ParticipantsSafety Run-InVanucizumab + mFOLFOX-6Bevacizumab + mFOLFOX-6
Percentage of Participants With Objective Response (ORR) as Assessed Using RECIST v. 1.162.5 (34.3 to 90.6)43.6 (33.59 to 53.64)51.6 (41.53 to 61.63)
SecondaryDuration of Objective Response, as Assessed Using RECIST v. 1.1

Efficacy of vanucizumab was evaluated in terms of duration of objective response as assessed using RECIST v. 1.1. This was computed using the PFS definition with death on study (deaths that occurred outside the 30 days window from the last study treatment are excluded).

Time frame:
Baseline (within 28 days prior to Day 1), then every 8 weeks until PD, start of other anticancer therapy, withdrawal of consent, or death (up to approximately 29 months)
Reported as:
Median · days
Duration of Objective Response, as Assessed Using RECIST v. 1.1
daysVanucizumab + mFOLFOX-6Bevacizumab + mFOLFOX-6
Duration of Objective Response, as Assessed Using RECIST v. 1.1342 (274 to 510)304 (220 to 366)
SecondaryOverall Survival (OS)

Efficacy of vanucizumab was evaluated in terms of OS as the time from randomization until death from any cause. 99999 = data not estimable due to the low number of deaths.

Time frame:
Baseline until death from any cause (maximum up to approximately 3.5 years)
Reported as:
Median · days
Overall Survival (OS)
daysVanucizumab + mFOLFOX-6Bevacizumab + mFOLFOX-6
Overall Survival (OS)746.0 (687.0 to NA)NA (723.0 to NA)
Statistical analysis
  • Vanucizumab + mFOLFOX-6 vs Bevacizumab + mFOLFOX-6 · Log Rank · p = = 0.5740 · Hazard ratio (hr): 0.85 · 95% CI 0.49 to 1.49
SecondaryPercentage of Participants With Adverse Events (AEs)

Safety is evaluated in terms of percentage of participants with at least one serious adverse event and percentage of participants with at least one adverse event.

Time frame:
Up to approximately 29 months
Reported as:
Number · Percentage of Participants
Percentage of Participants With Adverse Events (AEs)
Percentage of ParticipantsSafety Run-InVanucizumab + mFOLFOX-6Bevacizumab + mFOLFOX-6
Serious Adverse events37.549.543.2
Adverse events100100.0100.0
SecondaryNumber of Participants With Human Anti-human Antibodies (HAHAs) Against Vanucizumab

Safety is evaluated in terms of number of participants with Human Anti-human Antibodies (HAHAs) Against Vanucizumab.

Time frame:
End of study (EoS, within 28 to 42 days after last dose, latest at 29 months)
Reported as:
Count of participants · Participants
Number of Participants With Human Anti-human Antibodies (HAHAs) Against Vanucizumab
ParticipantsSafety Run-InVanucizumab + mFOLFOX-6
Number of Participants With Human Anti-human Antibodies (HAHAs) Against Vanucizumab21
SecondaryArea Under the Plasma Concentration-Time Curve (AUC) of Vanucizumab

PK profile of vanucizumab was evaluated in terms of AUC

Time frame:
Cycles 1 and 8 of parts 1 and 2
Reported as:
Geometric mean · hr*ug/ml
Area Under the Plasma Concentration-Time Curve (AUC) of Vanucizumab
hr*ug/mlSafety Run-InVanucizumab + mFOLFOX-6
Cycle 173600 ± 20.763500 ± 27.2
Cycle 8112000 ± 11.282100 ± 31.6
SecondaryMaximum Observed Plasma Concentration (Cmax) of Vanucizumab

PK profile of vanucizumab was evaluated in terms of Cmax

Time frame:
Cycles 1 and 8 of parts 1 and 2
Reported as:
Geometric mean · ug/ml
Maximum Observed Plasma Concentration (Cmax) of Vanucizumab
ug/mlSafety Run-InVanucizumab + mFOLFOX-6
Cycle 1463 ± 18.5500 ± 26.3
Cycle 8685 ± 17.6794 ± 38.2
SecondaryMinimum Observed Plasma Concentration (Clast) of Vanucizumab

PK profile of vanucizumab was evaluated in terms of Clast

Time frame:
Cycles 1 and 8 of parts 1 and 2
Reported as:
Geometric mean · ug/ml
Minimum Observed Plasma Concentration (Clast) of Vanucizumab
ug/mlVanucizumab + mFOLFOX-6
Cycle 1103 ± 67.2
Cycle 8361 ± 39.8
SecondaryTime to Reach Cmax (Tmax) of Vanucizumab

PK profile of vanucizumab was evaluated in terms of Tmax

Time frame:
Cycles 1 and 8 of parts 1 and 2
Reported as:
Median · hr
Time to Reach Cmax (Tmax) of Vanucizumab
hrSafety Run-InVanucizumab + mFOLFOX-6
Cycle 12.79 (1.50 to 7.67)2.05 (1.0 to 26.1)
Cycle 84.04 (0.5 to 5.25)1.58 (0.5 to 4.77)
SecondaryPlasma Terminal Half-Life (t1/2) of Vanucizumab

PK profile of vanucizumab was evaluated in terms of t1/2, values are reported for cycle 8 of both part 1 (safety run-in) and part 2 of the study.

Time frame:
Cycle 8
Reported as:
Geometric mean · hr
Plasma Terminal Half-Life (t1/2) of Vanucizumab
hrSafety Run-InVanucizumab + mFOLFOX-6
Plasma Terminal Half-Life (t1/2) of Vanucizumab202 ± 12.4157 ± 30.3
SecondaryPlasma Clearance at Steady State (CLss) of Vanucizumab

PK profile of vanucizumab was evaluated in terms of CLss, values are reported for cycle 8 of both part 1 (safety run-in) and part 2 of the study.

Time frame:
Cycle 8
Reported as:
Geometric mean · ml/hr
Plasma Clearance at Steady State (CLss) of Vanucizumab
ml/hrSafety Run-InVanucizumab + mFOLFOX-6
Plasma Clearance at Steady State (CLss) of Vanucizumab15.3 ± 26.718.0 ± 29.0
SecondaryVolume of Distribution at Steady State (Vss) of Vanucizumab

PK profile of vanucizumab was evaluated in terms of Vss, values are reported for cycle 8 of both part 1 (safety run-in) and part 2 of the study.

Time frame:
Cycle 8
Reported as:
Geometric mean · ml
Volume of Distribution at Steady State (Vss) of Vanucizumab
mlSafety Run-InVanucizumab + mFOLFOX-6
Volume of Distribution at Steady State (Vss) of Vanucizumab4400 ± 25.14140 ± 29.7
SecondaryCmax Accumulation Ratio (AR) of Vanucizumab

PK profile of vanucizumab was evaluated in terms of Cmax Ratio, values are reported for cycle 8 of both part 1 (safety run-in) and part 2 of the study.

Time frame:
Cycle 8
Reported as:
Geometric mean · Ratio
Cmax Accumulation Ratio (AR) of Vanucizumab
RatioSafety Run-InVanucizumab + mFOLFOX-6
Cmax Accumulation Ratio (AR) of Vanucizumab1.51 ± 27.21.63 ± 36.2

Adverse events

Collected over Up to 28 days after the last dose of study drug (maximum treatment time = approximately 29 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Run-In3/8 (37.5%)3/8 (37.5%)8/8 (100%)
Vanucizumab + mFOLFOX-624/93 (25.8%)46/93 (49.5%)91/93 (97.8%)
Bevacizumab + mFOLFOX-627/95 (28.4%)41/95 (43.2%)94/95 (98.9%)
Most frequent serious events
Showing 10 of 90
Most frequent serious events
EventSafety Run-InVanucizumab + mFOLFOX-6Bevacizumab + mFOLFOX-6
NeutropeniaBlood and lymphatic system disorders1/81/932/95
Cardiac failureCardiac disorders1/80/930/95
Intestinal obstructionGastrointestinal disorders1/83/933/95
NauseaGastrointestinal disorders1/81/930/95
VomitingGastrointestinal disorders1/81/931/95
Febrile NeutropeniaBlood and lymphatic system disorders0/80/935/95
PyrexiaGeneral disorders0/84/934/95
Urinary tract infectionInfections and infestations0/82/934/95
Intestinal perforationGastrointestinal disorders0/83/932/95
Large intestine perforationGastrointestinal disorders0/83/931/95
Most frequent other events
Showing 10 of 97
Most frequent other events
EventSafety Run-InVanucizumab + mFOLFOX-6Bevacizumab + mFOLFOX-6
DiarrhoeaGastrointestinal disorders6/856/9357/95
NauseaGastrointestinal disorders6/852/9355/95
DysgeusiaNervous system disorders5/816/9322/95
HypertensionVascular disorders5/842/9327/95
NeutropeniaBlood and lymphatic system disorders4/840/9343/95
Mucosal inflammationGeneral disorders4/823/9331/95
AstheniaGeneral disorders3/841/9342/95
AnaemiaBlood and lymphatic system disorders3/86/9312/95
ThrombocytopeniaBlood and lymphatic system disorders3/84/938/95
ConstipationGastrointestinal disorders3/826/9331/95

Baseline characteristics

Age, Continuous
Age, Continuous(years)Safety Run-InVanucizumab + mFOLFOX-6Bevacizumab + mFOLFOX-6Total
Mean63.3 ± 10.862.7 ± 11.062.3 ± 10.662.5 ± 0.2
Age, Customized
Age, Customized(Participants)Safety Run-InVanucizumab + mFOLFOX-6Bevacizumab + mFOLFOX-6Total
Adults (18-64 years)44853105
From 65-84 years4464292
Sex: Female, Male
Sex: Female, Male(Participants)Safety Run-InVanucizumab + mFOLFOX-6Bevacizumab + mFOLFOX-6Total
Female3385798
Male5563899
08

Study locations

39 sites
  • Alabama Oncology
    Birmingham, Alabama 35211, United States
  • Arizona Clinical Research Ctr
    Tucson, Arizona 85715, United States
  • California Cancer Associates for Research & Excellence, Inc.
    Encinitas, California 92008, United States
  • Fresno cCare
    Fresno, California 93720, United States
  • University of California San Diego Medical Center
    La Jolla, California 92093-5354, United States
  • Va Greater Los Angeles Healthcare System
    Sepulveda, California 91343, United States
  • SCRI Florida Cancer Specialists South
    Fort Myers, Florida 33916, United States
  • Ocala Oncology Center
    Ocala, Florida 34471, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Oncology Hematology Care Inc
    Cincinnati, Ohio 45242, United States
  • Sarah Cannon Research Inst.
    Nashville, Tennessee 37203, United States
  • Ctr for Cancer and Blood Disorders
    Fort Worth, Texas 76104, United States
  • Cancer Therapy & Research Center
    San Antonio, Texas 78229, United States
  • Northern Utah Associates
    Ogden, Utah 84403, United States
  • Calvary Mater Newcastle
    Waratah, New South Wales 2298, Australia
  • The Queen Elizabeth Hospital
    Woodville, South Australia 5011, Australia
  • Monash Medical Centre-Moorabbin Campus
    Clayton, Victoria 3168, Australia
  • Salzburger Landeskliniken LKH
    Salzburg, 5020, Austria
  • Oö. Gesundheits- und Spitals-AG/LKH Steyr
    Steyr, 4400, Austria
  • Imeldaziekenhuis
    Bonheiden, 2820, Belgium
  • Centre Paul Papin
    Angers Cedex 2, 49055, France
  • Institut De Cancerologie De L'Ouest; Medical Oncology
    Saint Herblain, 44115, France
  • Hospital Universitario Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
  • Hospital Universitario Marques de Valdecilla
    Santander, Cantabria 39008, Spain
  • Hospital Universitario Reina Sofia; Servicio de Oncologia
    Córdoba, Cordoba 14004, Spain
  • Hospital del Mar; Servicio de Oncologia
    Barcelona, 08003, Spain
  • Hospital Univ Vall d'Hebron; Servicio de Oncologia
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Institut Catala d Oncologia Hospital Duran i Reynals
    Barcelona, 08908, Spain
  • Hospital General Universitario Gregorio Marañon; Servicio de Oncologia
    Madrid, 28007, Spain
  • Hospital Universitario Clínico San Carlos; Servicio de Oncologia
    Madrid, 28040, Spain
  • HM Sanchinarro - CIOCC; Servicio de Oncologia
    Madrid, 28050, Spain
  • Hospital Universitario Virgen del Rocio
    Sevilla, 41013, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
  • Aberdeen Royal Infirmary; Medical Oncology Dept
    Aberdeen, AB25 2ZN, United Kingdom
  • Guys and St Thomas NHS Foundation Trust, Guys Hospital
    London, SE1 9RT, United Kingdom
  • Maidstone Hospital
    Maidstone, ME16 9QQ, United Kingdom
  • Queen's Hospital; Oncology
    Romford, RM7 0AG, United Kingdom
  • The Royal Marsden Hospital
    Sutton, SM2 5PT, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2014 to primary completion in Jul 2016, 24 months.

Results were first posted in Mar 2020, 3 years 7 months after primary completion. A results delay was requested in Jan 2018.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2014
First posted
May 19, 2014
StartActual
Jun 30, 2014
Primary completionActual
Jul 29, 2016
CompletionActual
Feb 1, 2017
Results delay requested
Jan 8, 2018
Results first posted
Mar 25, 2020
Last update
Mar 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02141295
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 19, 2014
Start date
Jun 30, 2014
Primary completion
Jul 29, 2016
Completion
Feb 1, 2017
Results posted
Mar 25, 2020
Last update
Mar 25, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oxaliplatin · Vanucizumab

Start the discussion